Amendments to the claims:

This listing of the claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A method of treating ~~and/or preventing~~ cerebral ischemia comprising the step of administering to a subject in need thereof a medicament comprising ~~as~~ a neuroprotective amount of an active ingredient comprising a hydrogenation product of *Boswellia serrata* obtained through the catalytic hydrogenation of ethanol extracts of frankincense (*Boswellia serrata*).

2. (Previously Presented) The method according to claim 1, wherein the cerebral ischemia occurs as a result of apoplexy.

3. (Previously Presented) The method according to claim 1, wherein the active ingredient comprises frankincense or a boswellic acid-containing vegetable extract.

4. (Previously Presented) The method according to claim 1, wherein the frankincense extract is selected from the group consisting of a keto-boswellic acid, 3-O-acetyl-11-keto-ß-boswellic acid, 11-keto-ß-boswellic acid, a physiologically acceptable salt of a keto-boswellic acid, a derivative of a keto-boswellic acid, a salt of a keto-boswellic acid derivative, and a keto-boswellic acid-containing vegetable extract.

5. (Previously Presented) The method according to claim 1, wherein the frankincense extract comprises a tirucallic acid, another triterpene or a salt or derivative thereof or a vegetable extract containing a tirucallic acid, another triterpene or a salt or derivative thereof.

6. (Previously Presented) The method according to claim 1, wherein the frankincense extract comprises an extract from a *Boswellia serrata* resin.

7. (Currently Amended) A method of treating ~~and/or preventing~~ a cranial/brain trauma, cerebral ischemia and/or Alzheimer's disease comprising the step of administering to a subject in need thereof a medicament comprising a neuroprotective amount of an active ingredient selected from the group consisting of: a hydrogenation products of a frankincense extracts~~, substances contained in frankincense, their~~ and a physiologically acceptable salts of said hydrogenation product~~, their derivatives, physiologically acceptable salts of said derivatives, pure boswellic acid, a physiologically acceptable salt of boswellic acid, a derivative of boswellic acid, a salt of a boswellic acid derivative, and a boswellic acid-containing vegetable preparation~~.

8. (Currently Amended) The method according to claim 7, wherein the medicament is used for ~~preventing and/or~~ treating Alzheimer's disease.

9. (Previously Presented) The method according to claim 7, wherein the active ingredient comprises a hydrogenation product of a boswellic acid-containing vegetable extract.

10. (Currently Amended) The method according to claim 7, wherein the active ingredient comprises a hydrogenated product of a frankincense extract obtained from a *Boswellia serrata* resin.

11. (Currently Amended) The method according to claim 7, wherein the active ingredient is selected from the group consisting of a hydrogenation product of boswellic acid~~,~~ and a physiologically acceptable salt of said hydrogenation product ~~of boswellic acid, a derivative thereof, a salt of a boswellic acid derivative, and a boswellic acid-containing vegetable preparation~~.

12. (Canceled) ~~The method according to claim 7, wherein the active ingredient comprises dihydroboswellic acid.~~

13. (Canceled) ~~The method according to claim 7, wherein the active ingredient comprises a hydrogenation product is selected from the group consisting of ß-dihydroboswellic acid acetate, ß-dihydroboswellic acid formate, ß-dihydroboswellic acid methyl ester, acetyl-ß-dihydroboswellic acid, α-dihydroboswellic acid, acetyl-α-dihydroboswellic acid and formyl-α-dihydroboswellic acid.~~

14. (Canceled) ~~The method according to claim 7, wherein the active ingredient is selected from the group consisting of a keto-dihydroboswellic acid, acetyl-11-keto-ß-dihydroboswellic acid, 11-keto-ß-dihydroboswellic acid, formyl-11-keto-ß-dihydroboswellic acid, a physiologically acceptable salt of a keto-dihydroboswellic acid, a derivative of a keto-dihydroboswellic acid, a salt of a keto-dihydroboswellic acid derivative, and a hydrogenated keto-boswellic acid-containing vegetable extract.~~

15. (Currently Amended) The method according to claim 7, wherein the active ingredient is selected from the group consisting of a hydrogenation product of tirucallic acid and a physiologically acceptable ~~, a~~ salt of said hydrogenation product~~, a derivative of said~~

~~hydrogenation product or salt thereof, and a hydrogenated tirucallic acid-containing vegetable extract.~~

16. (Previously Presented) The method according to claim 1, wherein the medicament is formulated for intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous, intrathecal or intracranial administration.

17. (Previously Presented) The method according to claim 1, wherein the medicament comprises a tablet or solution.

18. (Previously Presented) The method according to claim 7, wherein the medicament is formulated for intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous, intrathecal or intracranial administration.

19. (Previously Presented) The method according to claim 7, wherein the medicament comprises a tablet or solution.